Lilly Financial Results: Q2 2019
Lilly has announced its financial results, including earnings, for the second quarter of 2019.
"Lilly's portfolio of newer medicines reached more patients in the second quarter, allowing the company to grow revenue despite headwinds, including the expiration of the U.S. patent for Cialis," said Dave Ricks, Lilly's chairman and CEO. "We are continuing to make significant investments in our business to ensure the success of our recent product launches. At the same time, we are expanding investment in our pipeline in order to develop new medicines that have the potential to more effectively treat patients that have diabetes, cancer, autoimmune disorders and other serious conditions."
Read the press release
Listen to the investor webcast
Download the investor presentation
View Lilly's clinical development pipeline
Read Lilly executive committee biographies
- View Lilly's key facts
For more information, visit Lilly's Investor Relations website.